ãåãåãã å¶æ¥é£çµ¡çªå£ ä¿®çã»ç¹æ¤ã»ä¿å® FDA 21 CFR Part 11 㨠FTIR ã®å¯¾å¿ FTIRãã¦ãã¦ã»å®åç·¨ FTIR TALK LETTER volï¼3(2004) ä»åã¯ï¼ããæ°å¹´è£½è¬æ¥çã§è©±é¡ã«ãªã£ã¦ãã FDA 21 CFR Part 11 ã®æ¦è¦ã¨ FTIR ã§ã®å¯¾å¿ã«ã¤ãã¦ã話ãã¾ãã â» ãã®ãã¼ã¸ã®å 容ã¯2004å¹´ã«å½ç¤¾ããçºè¡ãããFTIR Talkã«æ²è¼ããããã®ã§ããè¨è¼ãã¦ããå ¨ã¦ã®å 容ã2004å¹´å½æã®ãã®ã§ãã FDA 21 CFR Part 11 ã¨ã¯ Food and Drug Administration ï¼FDA:ã¢ã¡ãªã«é£åå»è¬åå±ï¼ãï¼1990 年代ã«å種ç³è«æ¸é¡ã®ãã¼ãã¼ã¬ã¹åããããã¦ï¼å¾æ¥ã®ç´ãã¼ã¹ã§ã®è¨é²ãé»ååªä½ã«ç½®ãæããå ´åã®è¦æ±äºé ãè¦å®ãããã®ã§ï¼1997 å¹´ã«çºå¹ãã¦ãã¾ãã ç´ã«æ¸ããããã®ãããï¼é»ååã
{{#tags}}- {{label}}
{{/tags}}